Earnings ·
Denali Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, generating $3.6…
DNLIDenali Therapeutics Inc.
Denali Therapeutics Inc. reported financial results for the second quarter ended June 30, 2026, generating $3.6 million in net product revenue from its first full quarter of commercial sales for AVLAYAH, an enzyme replacement therapy for Hunter syndrome. The company recorded a net loss of $127.6 million and reported total research and development expenses of $97.0 million alongside selling, general, and administrative costs of $36.3 million. In July 2026, Denali received $195 million in gross proceeds from the sale of a Priority Review Voucher associated with AVLAYAH, bringing pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion. The company also announced that enrollment is complete for its Phase 1/2 study of DNL593 for frontotemporal dementia, with results now expected in 2027. Denali Therapeutics Inc. operates as a biotechnology company pioneering biotherapeutics designed to cross the blood-brain barrier using its proprietary TransportVehicle platform.